Acquired thrombocytopenia
MONDO:0001198An instance of thrombocytopenia that is acquired during the lifetime of the individual.
Also known as: acquired thrombocytopenia, secondary thrombocytopenia
25 clinical trials for this condition and its sub-types, 11 tagged with Acquired thrombocytopenia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Acquired thrombocytopenia
-
New drug could help liver disease patients avoid bleeding during surgery
Disease control CompletedThis study tests a drug called herombopag in people with chronic liver disease who have low platelet counts and need surgery. The goal is to see if the drug can safely raise platelet levels enough to reduce bleeding risk during the procedure. About 101 adults with mild to moderat…
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug could reduce need for plasma exchange in rare blood disorder
Disease control CompletedThis study tested a drug called TAK-755 in 29 adults with a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP). The goal was to see if TAK-755, along with standard immune-suppressing drugs, could control the disease with little or no pl…
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Breakthrough drug combo may replace plasma exchange for rare blood disease
Disease control CompletedThis study tested whether a drug called caplacizumab, combined with immune-suppressing medicines, could treat a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP) without the usual plasma exchange procedure. Fifty-one adults aged 18 to …
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug shows promise in preventing deadly blood clot relapses in japanese patients
Disease control CompletedThis study tested a drug called caplacizumab in 21 Japanese adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare condition causing dangerous blood clots. Participants received caplacizumab alongside standard treatments like plasma exchange and steroids. The goa…
Phase 2/3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Study reveals tricky platelet swings in blood disorder drug response
Knowledge-focused CompletedThis study looked back at 223 people with acquired thrombotic thrombocytopenic purpura (aTTP) who received caplacizumab (Cablivi). The drug quickly normalizes platelet counts, but some patients experience a sharp rise then a dip, which might mislead doctors into giving unnecessar…
Sponsor: University of Cologne • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:26 UTC